Business
CORCEPT THERAPEUTICS INC: We sell Korlym and a generic version of Korlym in the United States (our "Products") using sales representatives to call on physicians caring for patients with hypercortisolism.
Revenue increased 12.8% to $761.4M, while Net income decreased 29.4% to $99.7M.
The read at a glance✓ Audited against SEC data
- Scale — FY2025 revenue $761.4MOK
- Profitability — Net income $99.7MOK
- Cash generation — Free cash flow $141.8MOK
- Accounting — Distress-safe · no manipulation flag · earnings quality safeOK
- Insiders — 1 buys; 30 sells in 365 daysOK
- Capital — share repurchases were $172.9MNote
Leadership changes
From CORCEPT THERAPEUTICS INC's own filings, the day they're filed.
- Corcept Therapeutics Incorporated · Directors · departureeff. 2025-10-10
Latest filings
- 8-K · Company announcement2026-07-29
- 10-Q · Quarterly report2026-07-29
- 8-K · Company announcement2026-06-17
- 8-K · Company announcement2026-06-03
- 8-K · Company announcement2026-05-28
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about CORCEPT THERAPEUTICS INC, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.